Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.13−0.27 (-1.75%)
Close on Nov 18, 2026Market cap $2.03BP/E 6.6Yield –
Aurinia Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2019 it was -$63.67M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$63.67M | – |
| FY2018 | Dec 31, 2018 | -$51.64M | – |
| FY2017 | Dec 31, 2017 | -$41.19M | – |
| FY2016 | Dec 31, 2016 | -$18.73M | – |
See a number that looks wrong?